Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cilengitide for Subjects With Newly Diagnosed Glioblastoma and Methylated MGMT Gene Promoter - A Multicenter, Open-label, Controlled Phase III Study, Testing Cilengitide in Combination With Standard Treatment (Temozolomide With Concomitant Radiation Therapy, Followed by Temozolomide Maintenance Therapy) Versus Standard Treatment Alone (CENTRIC)
Brief Summary: CENTRIC is a Phase 3 clinical trial assessing efficacy and safety of the investigational integrin inhibitor, cilengitide, in combination with standard treatment versus standard treatment alone in newly diagnosed glioblastoma subjects with a methylated O6-methylguanine-deoxyribonucleic acid methyltransferase (MGMT) gene promoter in the tumor tissue.

The MGMT gene promoter is a section of deoxyribonucleic acid (DNA) that acts as a controlling element in the expression of MGMT. Methylation of the MGMT gene promoter has been found to be a predictive marker for benefit from temozolomide (TMZ) treatment.


Options:
A: Arm Label: Bevacizumab + RT + Temozolomide; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Temozolomide, Radiation: Radiation therapy | Arm Label: Placebo + RT + Temozolomide; Type: PLACEBO_COMPARATOR; Interventions: Drug: Temozolomide, Radiation: Radiation therapy, Drug: Placebo | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Bevacizumab + RT + Temozolomide | Intervention Type: DRUG; Name: Temozolomide; Assigned to Arm(s): Bevacizumab + RT + Temozolomide, Placebo + RT + Temozolomide | Intervention Type: RADIATION; Name: Radiation therapy; Assigned to Arm(s): Bevacizumab + RT + Temozolomide, Placebo + RT + Temozolomide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + RT + Temozolomide
B: Arm Label: Cilengitide + Temozolomide + Radiotherapy; Type: EXPERIMENTAL; Interventions: Drug: Cilengitide, Drug: Temozolomide, Radiation: Radiotherapy | Arm Label: Temozolomide + Radiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Temozolomide, Radiation: Radiotherapy | Intervention Type: DRUG; Name: Cilengitide; Assigned to Arm(s): Cilengitide + Temozolomide + Radiotherapy | Intervention Type: DRUG; Name: Temozolomide; Assigned to Arm(s): Cilengitide + Temozolomide + Radiotherapy, Temozolomide + Radiotherapy | Intervention Type: RADIATION; Name: Radiotherapy; Assigned to Arm(s): Cilengitide + Temozolomide + Radiotherapy, Temozolomide + Radiotherapy
C: Arm Label: Bevacizumab/Irinoecan; Type: EXPERIMENTAL; Interventions: Drug: Avastin + Campto / radiotherapy + Temodal + Avastin (4 cures) | Arm Label: Stupp; Type: ACTIVE_COMPARATOR; Interventions: Drug: Temodal/radiotherapy | Intervention Type: DRUG; Name: Avastin + Campto / radiotherapy + Temodal + Avastin (4 cures); Assigned to Arm(s): Bevacizumab/Irinoecan | Intervention Type: DRUG; Name: Temodal/radiotherapy; Assigned to Arm(s): Stupp
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab [Avastin], Drug: irinotecan | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: temozolomide | Intervention Type: DRUG; Name: bevacizumab [Avastin]; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: irinotecan; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: temozolomide; Assigned to Arm(s): 2

Answer: B